Ryan P Bingham

Ryan P Bingham

UNVERIFIED PROFILE

Are you Ryan P Bingham?   Register this Author

Register author
Ryan P Bingham

Ryan P Bingham

Publications by authors named "Ryan P Bingham"

Are you Ryan P Bingham?   Register this Author

8Publications

249Reads

19Profile Views

Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.

Bioorg Med Chem Lett 2019 Oct 7;29(20):126675. Epub 2019 Sep 7.

INSERM UMR1163 Laboratory of Genetic Skin Diseases, Imagine Institute and Université Paris Descarte-Sorbonne Paris Cité, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2019.126675DOI Listing
October 2019

Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.

Bioorg Med Chem Lett 2019 Jun 12;29(12):1454-1458. Epub 2019 Apr 12.

INSERM UMR1163 Laboratory of Genetic Skin Diseases, Imagine Institute and Université Paris Descarte - Sorbonne Paris Cité, Paris, France.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0960894X193024
Publisher Site
http://dx.doi.org/10.1016/j.bmcl.2019.04.022DOI Listing
June 2019

Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation.

Nat Chem Biol 2015 Mar 26;11(3):189-91. Epub 2015 Jan 26.

1] EpiNova DPU, Immuno-Inflammation Therapy Area, GlaxoSmithKline,Medicines Research Centre, Stevenage, Hertfordshire, UK. [2] AstraZeneca, Oncology iMed, Cambridge Science Park, Cambridge, UK (R.J.S. and D.M.W.); Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA (D.J.S.); University of Massachussetts Medical School, Worcester, Massachusetts, USA (P.R.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nchembio.1735DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397581PMC
March 2015